Skip to content
TheChatArchiveThe Chat Archive
Claudeclaude-1· AnthropicHugging Face Arena Human Preference 55K

KRAS inhibitors and AI

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Claudeclaude-2.0’s answer.
  1. User

    KRAS inhibitors and AI

  2. Claude Assistant

    KRAS inhibitors are a promising new class of targeted cancer therapies. KRAS is a commonly mutated oncogene in many cancers, including pancreatic, colorectal, and lung cancers. However, KRAS has been considered “undruggable” for a long time because its protein structure makes it difficult to target with small molecule inhibitors or antibodies.

    Recently, there have been some promising developments in KRAS inhibitors:

    • Small molecule inhibitors that target KRAS G12C mutations. These inhibitors bind to the mutated KRAS protein and inhibit its activity. Some candidates in clinical trials include AMG 510, MRTX849, and JNJ-74699157. Early results show some anti-tumor activity.

    • Inhibitors of KRAS membrane localization. Some approaches aim to prevent the KRAS protein from localizing to the cell membrane, which is required for its activity. Clinical candidates include Sotorasib.

    • Downstream signaling inhibitors. Other drugs target the downstream signaling pathways activated by KRAS, such as MEK inhibitors and ERK inhibitors. These include Ulixertinib and LY3214996.

    • Synthetic lethality approaches. Some therapies aim to target genes that are synthetically lethal with KRAS, meaning that inhibiting both genes leads to cell death but inhibiting either gene alone does not. An example is the combination of KRAS inhibitors with ATM inhibitors.

    Artificial intelligence has the potential to help with the discovery and development of KRAS inhibitors in several ways:

    • AI for drug discovery can help identify new small molecule inhibitors of KRAS through automated screening of large chemical libraries.

    • AI models can analyze the interactions between KRAS and potential inhibitors to gain insights into how to improve binding and potency.

    • AI can analyze large datasets from preclinical studies and clinical trials of KRAS inhibitors to identify biomarkers of response and mechanisms of resistance. This can help guide optimal patient selection and combination strategies.

    • AI for drug optimization and lead optimization can help optimize promising KRAS inhibitor leads to improve their drug-like properties and potency.

    So in summary, KRAS inhibitors are an exciting new area of development for targeted cancer drugs, and AI is poised to help accelerate progress in this field. But KRAS remains a challenging target, so more work is still needed.

  3. User

    give literatures

  4. Claude Assistant

    Here are some key review papers and studies on KRAS inhibitors and the role of AI:

    • A review on targeting KRAS G12C mutants with small molecule inhibitors:

    • A perspective on overcoming challenges of drugging KRAS and the promise of synthetic lethality approaches:

    • A review of computational approaches for developing KRAS inhibitors:

    • Case studies of using AI for optimizing and discovering KRAS inhibitors:

    • Clinical studies of KRAS G12C inhibitors:

    • Reviews on overcoming KRAS inhibitor resistance using combination strategies and biomarkers:

    This covers

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.